ACELYRIN Furthers Leadership Position Immunology with Acquisition of ValenzaBio
05 Jan 2023 //
BIOSPACE
ProBioGen & ValenzaBio Enter Second Service Agreement
14 Jun 2022 //
CONTRACTPHARMA
ValenzaBio Announces FDA Clearance of IND for VB421 in Thyroid Eye Disease
31 Mar 2022 //
BUSINESSWIRE
ValenzaBio, Novelty Nobility Announce Exclusive License Agreement
15 Feb 2022 //
BUSINESSWIRE
ValenzaBio, ProBioGen Enter Cell Line Pact
27 Jul 2021 //
CONTRACT PHARMA
Lonza and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421
18 Jun 2021 //
PRESS RELEASE